Amniotics presents promising PulmoStem™ data at ISHLT 2022
March 1, 2022
Amniotics AB (publ) (Nasdaq Stockholm: AMNI) today announced that an abstract with promising pre-clinical data on the effect of PulmoStem™ in lung transplantation has been accepted for an oral presentation at the International Society for Heart and Lung Transplantation (ISHLT) 42nd Annual Meeting & Scientific Sessions, which will be held on the April 27-30th in Boston.
The oral presentation at ISHLT2022 will be given by Dr. A. Niroomand, from the Lindstedt group at Lund University and Skåne University Hospital in Sweden and include new pre-clinical data on Amniotics biological therapy PulmoStem™. The effect of PulmoStem™ has been tested in a pre-clinical lung transplantation model using ARDS-damaged donor lungs, by Professor Sandra Lindstedt and her group at Lund University and Skåne University Hospital in Sweden.
"We are proud that these promising data on PulmoStem™ has been accepted for an oral presentation at ISHLT 2022. Lung transplantation has become an increasingly common procedure but is lagging behind other transplantations in terms of survival. The data being presented on PulmoStem™ at this meeting shows Amniotics commitment to help patients suffering from lung disease and to better understand how to advance the medical procedures in this space,” says CEO Kåre Engkilde
Lung transplantation is currently the only effective treatment for patients with end stage lung disease. However, most potential donor lungs are considered unsuitable for transplantation. Once a suitable donor lung is found, a transplantation can be made. Thereafter the patient undergoes a surgical procedure with the risk of developing PGD, which is a severe lung injury that occurs within the first 72 hours of lung transplantation and is the most common cause of early mortality and co-morbidity.
The oral presentation at ISHLT 2022 will be part of a session presenting novel translational research which advances the understanding of acute lung injury and Chronic Lung Allograft Dysfunction (CLAD) and highlights potential interventions for the salvage of un-transplantable donor lungs.
Session 06: Translational Insights into Lung Transplant Complications and Care
Presentation title: Mesenchymal Stromal Cell Therapy Regenerates Rejected Donor Lungs and Reduces Primary Graft Dysfunction Following Lung Transplantation
Presented by: A. Niroomand
Date: April 27th at 11:00-11:15